IFNB1 and COVID-19: Given that a diminished type I interferon response is implicated in COVID-19 (6, 10), and several clinical trials are underway to determine whether treatment with exogenous IFNβ can improve coronavirus outcomes (37, –39), we sought to investigate whether administration of IFNβ could improve Mφ-mediated inflammation, specifically in our obese, diabetic mice following coronavirus infection.